Physicians' Academy for Cardiovascular Education

Redefining intensive LDL-c management in high CV risk patients - The case for combination therapy

Meeting report with videos, slides and e-learning of a PACE-CME symposium during the ESC Congress 2021.

Discussion: Redefining intensive LDL-c management in high CV risk patients - The case for combination therapy

Oct. 13, 2021

Watch the discussion by the expert faculty of the symposium, chaired by prof. John Kastelein, Amsterdam, The Netherlands and speakers prof. Kausik Ray, London, UK, Derek Connolly, Birmingham, UK and prof. Christie Ballantyne, Houston, TX, USA.

E-learning Redefining intensive LDL-c management in high CV risk patients – The case for combination therapy

Accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Real-world evidence shows that the majority of patients do not achieve their LDL-c target goals. Where do we fall short in the need for combination therapy?

Expanding therapeutic options for LDL-c lowering

10' education - Oct. 1, 2021 - Prof. Christie Ballantyne, MD
The new therapeutic options for LDL-c lowering, bempedoic acid and inclisiran, are discussed by prof. Ballantyne. How do these drugs lower LDL-c and what are the findings in phase III programs?

The new therapeutic options for LDL-c lowering, bempedoic acid and inclisiran, are discussed by prof. Ballantyne. How do these drugs lower LDL-c and what are the findings in phase III programs?

Combination therapy with PCSK9 mAbs in post-MI patients

10' education - Sep. 22, 2021 - Derek Connolly, MD, PhD
Why should combination therapy, including PCSK9 monoclonal antibodies, be given to ACS patients? Derek Connolly sums up the evidence.

Why should combination therapy, including PCSK9 monoclonal antibodies, be given to ACS patients? Derek Connolly sums up the evidence. With question to test your knowledge.

Slides: Expanding therapeutic options for lowering LDL-c: Where will bempedoic acid and inclisiran contribute?

Slides (presentation) - Sep. 13, 2021 - Prof. Christie Ballantyne, MD - Houston, TX, USA - CME symposium held during ESC Congress 2021
This lecture by Prof. Christie Ballantyne was part of a EBAC-accredited symposium

Slides as educational service to PACE members and meeting participants.

Slides: The urgency to treat LDL C post MI: The role of PCSK9 Monoclonal antibodies in reaching goals

Slides (presentation) - Sep. 13, 2021 - Derek Connolly, MD, PhD - Birmingham, UK - CME symposium held during ESC Congress 2021
This lecture by Derek Connolly was part of a EBAC-accredited symposium

Slides as educational service to PACE members and meeting participants.

Slides: LDL C in the management of High CV Risk - Changing the Paradigm

Slides (presentation) - Sep. 7, 2021 - Prof. Kausik Ray, MD - London, UK - CME symposium held during ESC Congress 2021
This lecture by Prof. Kausik Ray was part of a EBAC-accredited symposium

Slides as educational service to PACE members and meeting participants.

Changing the paradigm on LDL-c-lowering in high CV risk patients

10' education - Sep. 7, 2021 - Prof. Kausik Ray, MD
Prof. Ray explains why monotherapy is not sufficient, and thus combination therapy is needed to reach LDL-c goals in patients with high CV risk.

Prof. Ray explains why monotherapy is not sufficient, and thus combination therapy is needed to reach LDL-c goals in patients with high CV risk.

Redefining intensive LDL-c management in high CV risk patients - The case for combination therapy